Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors
Ann Oncol
.
2021 Aug;32(8):1053-1055.
doi: 10.1016/j.annonc.2021.04.019.
Epub 2021 Apr 28.
Authors
J Barrière
1
,
E Chamorey
2
,
Z Adjtoutah
3
,
O Castelnau
4
,
A Mahamat
4
,
S Marco
4
,
E Petit
4
,
A Leysalle
5
,
V Raimondi
3
,
M Carles
6
Affiliations
1
Department of Medical Oncology, Clinique Saint Jean, Cagnes-sur-Mer, France. Electronic address:
[email protected]
.
2
Department of Biostatistics and Epidemiology, Centre Antoine Lacassagne, Nice, France.
3
Department of Biology, Cerballiance, Cagnes-sur-Mer, France.
4
Department of Medical Oncology, Clinique Saint Jean, Cagnes-sur-Mer, France.
5
Department of Radiation Oncology, Clinique Saint Jean, Cagnes-sur-Mer, France.
6
Department of Infectious Disease, Centre Hospitalo-Universitaire de Nice, Nice, France.
PMID:
33932508
PMCID:
PMC8080507
DOI:
10.1016/j.annonc.2021.04.019
No abstract available
Publication types
Letter
MeSH terms
Antibodies, Viral
BNT162 Vaccine
COVID-19 Vaccines
COVID-19*
Humans
Neoplasms* / drug therapy
Vaccines*
Substances
Antibodies, Viral
COVID-19 Vaccines
Vaccines
BNT162 Vaccine